143 related articles for article (PubMed ID: 38580786)
21. Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).
Marcellin F; Mourad A; Lemoine M; Kouanfack C; Seydi M; Carrieri P; Attia A; Protopopescu C; Lacombe K; Boyer S
JHEP Rep; 2023 Mar; 5(3):100665. PubMed ID: 36686592
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Grotzinger KM; Younossi ZM; Giannini EG; Chen PJ; Rendas-Baum R; Theodore D
Health Qual Life Outcomes; 2016 Mar; 14():49. PubMed ID: 27004952
[TBL] [Abstract][Full Text] [Related]
23. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.
Mathew A; Peiffer LP; Rhoades K; McGarrity TJ
Health Qual Life Outcomes; 2006 May; 4():30. PubMed ID: 16696859
[TBL] [Abstract][Full Text] [Related]
24. Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF; Lapidus N; Dorival C; Diallo A; Amri I; Fontaine H; Pol S; Carrat F;
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):797-805. PubMed ID: 29749668
[TBL] [Abstract][Full Text] [Related]
25. Discordance Abounds in Minimum Clinically Important Differences in THA: A Systematic Review.
Deckey DG; Verhey JT; Christopher ZK; Gerhart CRB; Clarke HD; Spangehl MJ; Bingham JS
Clin Orthop Relat Res; 2023 Apr; 481(4):702-714. PubMed ID: 36398323
[TBL] [Abstract][Full Text] [Related]
26. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
Juanbeltz R; Martínez-Baz I; San Miguel R; Goñi-Esarte S; Cabasés JM; Castilla J
PLoS One; 2018; 13(10):e0205277. PubMed ID: 30300395
[TBL] [Abstract][Full Text] [Related]
27. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
28. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
[TBL] [Abstract][Full Text] [Related]
29. Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection.
Yi CH; Bair MJ; Wang JH; Wong MW; Liu TT; Lei WY; Liang SW; Lin L; Hung JS; Huang JF; Hsu YC; Chen CL
J Microbiol Immunol Infect; 2022 Aug; 55(4):643-650. PubMed ID: 35637143
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
Laurain A; Metivier S; Haour G; Larrey D; Dorival C; Hezode C; Zoulim F; Marcellin P; Bourliere M; Zarski JP; Thabut D; Alric L; Ganne-Carrie N; Cales P; Bronowicki JP; Riachi G; Geist C; Causse X; Abergel A; Chazouilleres O; Mathurin P; Guyader D; Samuel D; Tran A; Loustaud-Ratti V; Petrov-Sanchez V; Diallo A; Luzivika-Nzinga C; Fontaine H; Carrat F; Pol S;
BMC Infect Dis; 2019 Apr; 19(1):300. PubMed ID: 30940090
[TBL] [Abstract][Full Text] [Related]
31. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents.
Goñi Esarte S; Juanbeltz R; Martínez-Baz I; Castilla J; San Miguel R; Herrero JI; Zozaya JM
Rev Esp Enferm Dig; 2019 Jun; 111(6):445-452. PubMed ID: 31066286
[TBL] [Abstract][Full Text] [Related]
32. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012143. PubMed ID: 28585310
[TBL] [Abstract][Full Text] [Related]
33. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
Cheng Q; Cunningham EB; Shih S; Amin J; Bruneau J; Artenie AA; Powis J; Litwin AH; Cooper C; Dalgard O; Hellard M; Bruggmann P; Marks P; Lacombe K; Stedman C; Read P; Hajarizadeh B; Dunlop AJ; Conway B; Feld JJ; Dore GJ; Grebely J;
Value Health; 2023 Jun; 26(6):883-892. PubMed ID: 36646278
[TBL] [Abstract][Full Text] [Related]
34. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
[No Abstract] [Full Text] [Related]
35. Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.
Kawakubo M; Eguchi Y; Okada M; Iwane S; Oeda S; Otsuka T; Nakashita S; Araki N; Koga A
Intern Med; 2018 Jul; 57(14):1959-1966. PubMed ID: 29526929
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct-acting antiviral agents.
Karimi-Sari H; Hosseini MA; Nikjoo N; Bagheri Baghdasht MS; Alavian SM
Clin Microbiol Infect; 2020 Aug; 26(8):1093.e5-1093.e8. PubMed ID: 32353413
[TBL] [Abstract][Full Text] [Related]
37. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.
Rojas Rojas T; Di Beo V; Delorme J; Barre T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B; Marcellin F
Int J Drug Policy; 2019 Oct; 72():61-68. PubMed ID: 31129024
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
39. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
40. What Are the Minimal and Substantial Improvements in the HOOS and KOOS and JR Versions After Total Joint Replacement?
Lyman S; Lee YY; McLawhorn AS; Islam W; MacLean CH
Clin Orthop Relat Res; 2018 Dec; 476(12):2432-2441. PubMed ID: 30179951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
